Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Spruce Biosciences (SPRB) Operating Expenses (2022 - 2025)

Spruce Biosciences (SPRB) has disclosed Operating Expenses for 4 consecutive years, with $11.1 million as the latest value for Q4 2025.

  • On a quarterly basis, Operating Expenses fell 55.19% to $11.1 million in Q4 2025 year-over-year; TTM through Dec 2025 was $36.5 million, a 40.2% decrease, with the full-year FY2025 number at $36.5 million, down 40.2% from a year prior.
  • Operating Expenses was $11.1 million for Q4 2025 at Spruce Biosciences, up from $8.2 million in the prior quarter.
  • In the past five years, Operating Expenses ranged from a high of $24.8 million in Q4 2024 to a low of $2.7 million in Q2 2025.
  • A 4-year average of $12.9 million and a median of $12.0 million in 2022 define the central range for Operating Expenses.
  • Peak YoY movement for Operating Expenses: skyrocketed 76.29% in 2024, then crashed 76.88% in 2025.
  • Spruce Biosciences' Operating Expenses stood at $12.1 million in 2022, then rose by 16.03% to $14.1 million in 2023, then surged by 76.29% to $24.8 million in 2024, then crashed by 55.19% to $11.1 million in 2025.
  • Per Business Quant, the three most recent readings for SPRB's Operating Expenses are $11.1 million (Q4 2025), $8.2 million (Q3 2025), and $2.7 million (Q2 2025).